View Filing Data

$ 593,124

^[1]

$ 539,884

$ 494,188

Exercise of stock options and related tax benefit

3,681

2,909

2,659

44,905

19,072

35,070

Stock compensation expense

(50,000)

(40,000)

(59,998)

10,810

10,267

10,181

Impact of defined benefit plans, net of tax

79,980

58,370

59,304

555

(309)

(697)

Foreign currency translation adjustment

6,380

2,599

(10,045)

Unrealized loss (gain) on hedges, net of tax

(4,068)

(477)

4,858

Reclassification of hedge loss to earnings, net of tax

769

809

4,364

686,136

593,124

^[1]

539,884

Common Stock

Beginning Balance, Shares

$ 255

$ 256

25,441

25,622

25,695

Employee stock purchase plan, Shares

$ 1

Exercise of stock options and related tax benefit

$ 9

$ 5

$ 10

Exercise of stock options and related tax benefit, Shares

1,012

488

950

Shares repurchased, Shares

$ (9)

$ (7)

$ (11)

(907)

(735)

(1,100)

Issuance of restricted stock, net of cancellations, shares

Additional Paid-in Capital

$ 256

$ 255

$ 256

Ending Balance, Shares

25,660

25,441

25,622

$ 252,323

$ 226,829

$ 186,933

Exercise of stock options and related tax benefit

3,680

2,908

2,658

44,896

19,067

35,060

Stock compensation expense

(9,000)

(6,748)

(8,003)

10,810

10,267

10,181

302,709

252,323

226,829

Retained Earnings

334,641

309,516

302,196

(40,991)

(33,245)

(51,984)

79,980

58,370

59,304

Accumulated Other Comprehensive Income/(Loss)

373,630

334,641

309,516

Impact of defined benefit plans, net of tax

5,905

3,283

4,803

555

(309)

(697)

Foreign currency translation adjustment

6,380

2,599

(10,045)

Unrealized loss (gain) on hedges, net of tax

(4,068)

(477)

4,858

Reclassification of hedge loss to earnings, net of tax

769

809

4,364

9,541

5,905

3,283

Comprehensive Income

Impact of defined benefit plans, net of tax

79,980

58,370

59,304

555

(309)

(697)

Foreign currency translation adjustment

6,380

2,599

(10,045)

Unrealized loss (gain) on hedges, net of tax

(4,068)

(477)

4,858

Reclassification of hedge loss to earnings, net of tax

769

809

4,364

Comprehensive income

$ 83,616

$ 60,992

$ 57,784

[1]	Certain balances were revised to reflect updates to our purchase price allocation of our Global Med acquisition - See Note 3, Acquisitions.

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

12 Months Ended

Apr. 02, 2011

Apr. 03, 2010

Mar. 28, 2009

Cash Flows from Operating Activities:

Depreciation and amortization

$ 79,980

$ 58,370

$ 59,304

Non cash items:

48,145

43,236

36,462

Stock compensation expense

10,810

10,267

10,181

Deferred tax expense

5,782

2,592

1,645

Loss/(gain) on sales of property, plant and equipment

674

(435)

(124)

Unrealized gain from hedging activities

(614)

(1,368)

3,812

Contingent consideration income

(1,894)

(2,345)

(Reversal)/accretion of interest expense on contingent consideration

(416)

588

Asset impairment

15,686

Change in operating assets and liabilities:

(Increase)/decrease in accounts receivable, net

(3,920)

4,364

(Increase)/decrease in inventories

(2,560)

(1,665)

(11,236)

Decrease in prepaid income taxes

1,680

7,254

(2,913)

Decrease in other assets and other long-term liabilities

(470)

(13,809)

(4,241)

Tax benefit of exercise of stock options

4,941

2,670

3,368

(Decrease)/increase in accounts payable and accrued expenses

(18,683)

5,263

20,104

Net cash provided by operating activities

123,455

130,668

116,364

Cash Flows from Investing Activities:

Capital expenditures on property, plant and equipment

(46,669)

(56,304)

(56,379)

Proceeds from sale of property, plant and equipment

1,468

1,785

2,383

Acquisition of ACCS

(6,229)

Acquisition of Global Med Technologies

(128)

(58,052)

Acquisition of SEBRA

(12,845)

Acquisition of Neoteric

(6,613)

Acquisition of Altivation

(3,545)

Acquisition of Medicell

(306)

(2,459)

Net cash used in investing activities

(51,558)

(132,335)

(60,000)

Cash Flows from Financing Activities:

Payments on long-term real estate mortgage

(632)

(754)

(694)

Net (decrease)/increase in short-term loans

(15,153)

6,184

(5,580)